论文部分内容阅读
目的讨论布地奈德联合重组人干扰素α-2b雾化吸入治疗小儿毛细支气管炎的临床疗效。方法 90例小儿毛细支气管炎患儿,随机分为观察组与对照组,各45例。对照组患儿使用布地奈德雾化吸入进行治疗,观察组患儿使用地奈德联合重组人干扰素α-2b雾化吸入进行治疗,比较两组患儿治疗后的效果以及哮憋、哮鸣音消失时间和住院时间。结果治疗后,观察组患儿显效30例,有效13例,无效2例,治疗总有效率为95.6%,对照组患儿显效20例,有效17例,无效8例,总有效率为82.2%;观察组患儿的总有效率明显高于对照组,差异有统计学意义(P<0.05)。观察组患儿哮憋、哮鸣音消失时间以及住院时间均短于对照组,差异有统计学意义(P<0.05)。结论小儿毛细支气管炎应用布地奈德联合重组人干扰素α-2b雾化吸入治疗能够有效改善患儿病症情况,提高治疗的效果,值得推广。
Objective To discuss the clinical efficacy of budesonide combined with recombinant interferon α-2b aerosol inhalation in the treatment of children with bronchiolitis. Methods Ninety children with bronchiolitis were randomly divided into observation group and control group, 45 cases each. Children in the control group were treated with inhaled budesonide inhalation. The patients in the observation group were treated with inhaled inhalation of desonide combined with recombinant interferon alfa-2b. The effects of the two groups of children after treatment were compared with those of asthma, Beep time and hospitalization time. Results After treatment, the observation group of children markedly effective in 30 cases, effective in 13 cases, 2 cases of ineffective, the total effective rate was 95.6%, control group of children markedly effective in 20 cases, effective in 17 cases, 8 cases, the total effective rate was 82.2% The total effective rate in observation group was significantly higher than that in control group, the difference was statistically significant (P <0.05). Asthmatic children in observation group, disappearance of wheeze and hospitalization time were shorter than the control group, the difference was statistically significant (P <0.05). Conclusion The use of budesonide combined with recombinant human interferon α-2b nebulization in children with bronchiolitis can effectively improve the condition of children and improve the treatment effect, which is worthy of popularization.